Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation

2026-08-27
Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

2026-08-26
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

2026-08-24
Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

1 Healthcare Stock to Target This Week and 2 Facing Headwinds

2026-08-20
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup

2026-08-20
Dexcom (DXCM) passes strong growth & technical screens with high scores, solid fundamentals, and a bull flag breakout setup.

Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?

2026-08-19
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow

2026-08-18
DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...

DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?

2026-08-17
DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...

DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates

2026-08-17
DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...

1 Surging Stock Worth Your Attention and 2 We Question

2026-08-16
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.